

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	14.6	103.0	(57.6-169.9)	Male	12	9.9	121.3	(62.6-211.9)
Female	7	5.3	131.2	(52.6-270.3)	Female	9	8.3	108.9	(49.7-206.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.1	nc	(nc-nc)	Male	6	3.1	193.4	(70.6-420.9)
Female	4	2.7	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	4	8.9	nc	(nc-nc)
Female	62	63.6	97.4	(74.7-124.9)	Female	5	7.7	64.5	(20.8-150.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	6	7.5	79.5	(29.0-173.0)
<u>Colon / Rectum</u>					Female	4	3.3	nc	(nc-nc)
Male	19	16.4	116.0	(69.8-181.2)	<u>Ovary</u>				
Female	24	16.2	148.5	(95.1-221.0)	Female	7	5.6	124.4	(49.8-256.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.1	120.9	(39.0-282.2)	Male	8	5.3	151.1	(65.0-297.7)
Female	0	1.1	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	55	54.7	100.6	(75.8-130.9)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.5	nc	(nc-nc)
Male	14	8.9	158.1	(86.4-265.3)	Female	4	2.1	nc	(nc-nc)
Female	8	4.9	161.7	(69.6-318.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	0.7	812.9	(296.8-1769.3)	Male	5	4.2	117.9	(38.0-275.0)
<u>Leukemia</u>					Female	17	12.6	134.4	(78.3-215.2)
Male	1	6.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	4.7	170.4	(73.4-335.9)	Female	20	14.8	135.3	(82.6-208.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.5	91.3	(29.4-213.0)	Male	227	204.2	111.2	(97.2-126.6)
Female	2	1.8	nc	(nc-nc)	Female	250	211.4	118.3	(104.1-133.9)
<u>Lung and Bronchus</u>									
Male	41	26.6	154.0	(110.5-209.0)					
Female	36	28.2	127.7	(89.4-176.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	20.8	81.8	(47.6-131.0)	Male	14	14.3	97.9	(53.5-164.2)
Female	7	7.2	97.7	(39.1-201.3)	Female	18	11.3	159.9	(94.7-252.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.6	152.8	(61.2-314.9)	Male	4	4.5	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	5	3.3	149.4	(48.1-348.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	17	12.9	131.7	(76.7-210.9)
Female	96	91.5	104.9	(85.0-128.1)	Female	11	10.6	103.8	(51.8-185.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.2	nc	(nc-nc)	Male	12	11.1	108.1	(55.8-188.9)
<u>Colon / Rectum</u>					Female	4	4.6	nc	(nc-nc)
Male	16	24.3	65.9	(37.6-107.0)	<u>Ovary</u>				
Female	17	22.7	74.8	(43.5-119.7)	Female	15	7.9	189.9	(106.2-313.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.9	102.3	(37.3-222.6)	Male	7	7.6	92.2	(36.9-190.0)
Female	4	1.4	nc	(nc-nc)	Female	6	7.2	83.6	(30.5-182.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.8	nc	(nc-nc)	Male	73	76.0	96.1	(75.3-120.8)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	5.1	nc	(nc-nc)
Male	8	12.8	62.5	(26.9-123.2)	Female	2	2.9	nc	(nc-nc)
Female	7	6.9	101.7	(40.7-209.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.2	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	7	6.2	113.1	(45.3-233.0)
<u>Leukemia</u>					Female	15	17.5	85.5	(47.8-141.1)
Male	7	8.9	78.7	(31.5-162.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	6.1	195.6	(100.9-341.7)	Female	19	20.4	92.9	(55.9-145.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	8.1	nc	(nc-nc)	Male	242	292.2	82.8	(72.7-93.9)
Female	3	2.4	nc	(nc-nc)	Female	292	293.9	99.3	(88.3-111.4)
<u>Lung and Bronchus</u>									
Male	20	37.8	52.9	(32.3-81.8)					
Female	24	38.6	62.2	(39.8-92.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	12.6	150.4	(90.5-234.8)	Male	8	7.9	100.9	(43.4-198.8)
Female	4	4.4	nc	(nc-nc)	Female	6	6.1	98.8	(36.1-215.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.1	140.2	(67.1-257.9)
Female	44	48.6	90.6	(65.8-121.6)	Female	7	6.1	115.6	(46.3-238.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	0	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.6	nc	(nc-nc)
Male	15	13.4	112.1	(62.7-184.9)	<u>Ovary</u>				
Female	12	12.9	92.7	(47.8-161.9)	Female	4	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.2	nc	(nc-nc)	Male	7	4.4	159.2	(63.8-328.1)
Female	0	0.9	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	51	39.8	128.1	(95.4-168.5)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.9	nc	(nc-nc)
Male	9	6.6	136.7	(62.4-259.6)	Female	1	1.6	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	9	8.5	105.3	(48.1-199.9)
Male	5	5.0	100.0	(32.2-233.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.4	176.5	(64.4-384.1)	Female	9	11.1	80.8	(36.9-153.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.1	nc	(nc-nc)	Male	182	160.3	113.5	(97.6-131.3)
Female	0	1.4	nc	(nc-nc)	Female	151	163.2	92.5	(78.3-108.5)
<u>Lung and Bronchus</u>									
Male	29	21.9	132.4	(88.6-190.1)					
Female	22	23.8	92.3	(57.8-139.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.6	83.1	(35.8-163.8)	Male	3	6.1	nc	(nc-nc)
Female	6	3.8	160.0	(58.4-348.2)	Female	4	5.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.5	91.0	(29.3-212.3)
Female	35	39.5	88.6	(61.7-123.3)	Female	8	5.1	157.2	(67.7-309.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	2.1	nc	(nc-nc)
Male	12	10.5	113.9	(58.8-199.0)	<u>Ovary</u>				
Female	14	11.4	122.8	(67.1-206.0)	Female	3	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.6	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	3.7	133.7	(43.1-311.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	38	33.2	114.3	(80.9-157.0)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	3	5.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	7.0	100.6	(40.3-207.2)
Male	3	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	6	8.7	69.3	(25.3-150.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.3	nc	(nc-nc)	Male	125	126.8	98.6	(82.1-117.5)
Female	0	1.1	nc	(nc-nc)	Female	145	135.6	107.0	(90.3-125.8)
<u>Lung and Bronchus</u>									
Male	18	17.2	104.7	(62.0-165.5)					
Female	32	19.7	162.3	(111.0-229.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	32.4	111.2	(77.9-154.0)	Male	20	20.7	96.7	(59.0-149.3)
Female	11	13.6	81.1	(40.4-145.2)	Female	16	17.9	89.5	(51.1-145.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.1	81.8	(26.4-191.0)	Male	9	6.5	137.7	(62.8-261.3)
Female	3	5.5	nc	(nc-nc)	Female	5	6.0	83.1	(26.8-193.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	23	18.5	124.3	(78.8-186.5)
Female	153	139.6	109.6	(92.9-128.4)	Female	19	18.3	103.7	(62.4-162.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	4.5	201.1	(91.8-381.9)	Male	23	15.0	153.5	(97.2-230.3)
<u>Colon / Rectum</u>					Female	13	7.6	170.1	(90.5-290.9)
Male	43	34.8	123.4	(89.3-166.2)	<u>Ovary</u>				
Female	35	41.1	85.2	(59.3-118.5)	Female	12	12.6	95.1	(49.1-166.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	8.6	58.2	(18.8-135.9)	Male	11	11.4	96.6	(48.1-172.8)
Female	3	2.6	nc	(nc-nc)	Female	17	13.8	123.5	(71.9-197.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	92	108.6	84.7	(68.3-103.9)
Female	3	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	7.6	144.8	(72.2-259.2)
Male	23	17.6	130.7	(82.8-196.2)	Female	5	5.3	93.7	(30.2-218.6)
Female	7	11.2	62.5	(25.0-128.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.0	nc	(nc-nc)
Male	7	5.0	140.0	(56.1-288.5)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	7	7.9	88.8	(35.6-183.0)
<u>Leukemia</u>					Female	19	24.0	79.2	(47.6-123.6)
Male	13	12.9	101.0	(53.7-172.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	10.6	84.6	(38.6-160.6)	Female	28	31.7	88.3	(58.6-127.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	11.2	80.0	(36.5-151.9)	Male	448	423.2	105.9	(96.3-116.1)
Female	3	4.1	nc	(nc-nc)	Female	490	482.5	101.6	(92.8-111.0)
<u>Lung and Bronchus</u>									
Male	82	57.6	142.3	(113.2-176.6)					
Female	84	68.3	122.9	(98.1-152.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	14.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	9	10.0	90.0	(41.1-170.9)
<u>Lung and Bronchus</u>									
Male	0	2.1	nc	(nc-nc)					
Female	0	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	13.6	169.7	(107.5-254.7)	Male	8	9.9	80.6	(34.7-158.8)
Female	10	6.0	167.8	(80.3-308.6)	Female	6	9.0	66.6	(24.3-145.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	6	2.8	218.0	(79.6-474.6)	Female	0	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	8.9	124.2	(61.9-222.2)
Female	77	70.3	109.5	(86.4-136.8)	Female	11	8.6	128.1	(63.9-229.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	12	7.9	151.2	(78.1-264.2)
<u>Colon / Rectum</u>					Female	5	3.7	136.9	(44.1-319.4)
Male	24	16.0	149.6	(95.8-222.6)	<u>Ovary</u>				
Female	25	18.6	134.2	(86.8-198.1)	Female	5	6.2	81.0	(26.1-189.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.1	nc	(nc-nc)	Male	9	5.1	175.1	(79.9-332.4)
Female	1	1.2	nc	(nc-nc)	Female	7	6.0	116.4	(46.6-239.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	61	54.8	111.4	(85.2-143.1)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.4	nc	(nc-nc)
Male	4	9.1	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.6	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	5	4.6	108.7	(35.0-253.6)
<u>Leukemia</u>					Female	16	13.7	116.9	(66.8-189.8)
Male	8	6.0	133.2	(57.4-262.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.0	140.1	(56.1-288.7)	Female	11	15.7	69.9	(34.8-125.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.7	nc	(nc-nc)	Male	237	202.7	116.9	(102.5-132.8)
Female	3	1.9	nc	(nc-nc)	Female	252	233.2	108.1	(95.1-122.3)
<u>Lung and Bronchus</u>									
Male	31	25.7	120.7	(82.0-171.4)					
Female	40	31.3	127.9	(91.4-174.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	18.6	86.0	(49.1-139.7)	Male	11	12.4	88.4	(44.1-158.2)
Female	3	7.1	nc	(nc-nc)	Female	13	12.0	108.7	(57.8-185.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.8	nc	(nc-nc)	Male	5	3.7	136.2	(43.9-317.9)
Female	1	4.4	nc	(nc-nc)	Female	0	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	12.0	49.9	(18.2-108.6)
Female	72	75.9	94.8	(74.2-119.4)	Female	15	10.5	142.3	(79.6-234.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	9	8.7	103.9	(47.4-197.2)
<u>Colon / Rectum</u>					Female	3	4.4	nc	(nc-nc)
Male	16	19.7	81.3	(46.4-132.0)	<u>Ovary</u>				
Female	25	21.5	116.2	(75.2-171.5)	Female	12	7.6	158.1	(81.6-276.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.9	nc	(nc-nc)	Male	9	6.5	138.9	(63.4-263.8)
Female	0	1.3	nc	(nc-nc)	Female	7	7.0	99.5	(39.9-205.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	3.8	nc	(nc-nc)	Male	47	62.6	75.1	(55.2-99.9)
Female	0	4.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.3	nc	(nc-nc)
Male	5	10.0	49.9	(16.1-116.4)	Female	1	2.9	nc	(nc-nc)
Female	5	6.2	80.2	(25.9-187.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	6.9	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	6	5.7	105.7	(38.6-230.0)
<u>Leukemia</u>					Female	4	19.7	nc	(nc-nc)
Male	10	9.2	109.2	(52.3-200.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.0	71.8	(23.1-167.6)	Female	12	17.6	68.1	(35.1-118.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.5	nc	(nc-nc)	Male	179	258.3	69.3	(59.5-80.2)
Female	2	2.4	nc	(nc-nc)	Female	225	277.8	81.0	(70.7-92.3)
<u>Lung and Bronchus</u>									
Male	15	33.3	45.0	(25.2-74.2)					
Female	20	37.0	54.1	(33.0-83.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	34.6	72.3	(46.8-106.8)	Male	23	22.5	102.4	(64.9-153.7)
Female	9	13.3	67.7	(30.9-128.6)	Female	27	19.0	141.9	(93.5-206.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.8	102.5	(41.1-211.3)	Male	9	7.2	125.3	(57.2-237.8)
Female	5	6.0	83.2	(26.8-194.1)	Female	9	6.0	148.8	(67.9-282.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	26	20.2	128.8	(84.1-188.7)
Female	159	153.8	103.4	(87.9-120.8)	Female	21	18.8	111.8	(69.2-171.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.1	nc	(nc-nc)	Male	17	16.8	101.3	(59.0-162.1)
<u>Colon / Rectum</u>					Female	4	8.0	nc	(nc-nc)
Male	30	38.1	78.8	(53.1-112.5)	<u>Ovary</u>				
Female	29	40.7	71.3	(47.7-102.4)	Female	14	13.5	103.9	(56.7-174.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	9.5	84.6	(36.4-166.7)	Male	11	12.3	89.3	(44.5-159.7)
Female	4	2.6	nc	(nc-nc)	Female	11	13.4	82.3	(41.0-147.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.5	nc	(nc-nc)	Male	113	122.1	92.6	(76.3-111.3)
Female	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	8.2	61.0	(19.7-142.4)
Male	18	19.6	91.6	(54.3-144.8)	Female	4	5.2	nc	(nc-nc)
Female	11	12.0	91.8	(45.8-164.3)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.2	166.9	(66.9-343.9)
Male	3	5.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.8	nc	(nc-nc)	Male	15	8.9	168.8	(94.4-278.5)
<u>Leukemia</u>					Female	37	27.6	134.2	(94.5-185.0)
Male	20	14.0	143.3	(87.5-221.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	10.9	91.5	(43.8-168.3)	Female	24	34.8	69.0	(44.2-102.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	12.5	64.1	(27.6-126.3)	Male	421	464.5	90.6	(82.2-99.7)
Female	3	4.3	nc	(nc-nc)	Female	454	509.6	89.1	(81.1-97.7)
<u>Lung and Bronchus</u>									
Male	38	62.4	60.9	(43.1-83.6)					
Female	38	70.6	53.8	(38.1-73.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.4	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	45.9	93.7	(67.8-126.2)	Male	25	29.8	83.9	(54.3-123.8)
Female	16	17.8	89.9	(51.3-145.9)	Female	26	25.4	102.3	(66.8-149.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	9.0	89.1	(38.4-175.7)	Male	10	9.3	107.8	(51.6-198.2)
Female	9	7.7	117.1	(53.4-222.3)	Female	4	8.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.6	nc	(nc-nc)	Male	19	26.7	71.2	(42.8-111.2)
Female	212	195.0	108.7	(94.6-124.4)	Female	33	24.9	132.4	(91.1-185.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	6.9	nc	(nc-nc)	Male	19	21.3	89.4	(53.8-139.6)
<u>Colon / Rectum</u>					Female	15	10.5	142.9	(79.9-235.8)
Male	43	50.2	85.7	(62.0-115.4)	<u>Ovary</u>				
Female	45	54.8	82.1	(59.9-109.9)	Female	16	17.4	91.8	(52.4-149.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	12.0	108.5	(57.7-185.5)	Male	18	16.1	111.8	(66.2-176.8)
Female	2	3.5	nc	(nc-nc)	Female	21	18.2	115.5	(71.5-176.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.5	nc	(nc-nc)	Male	149	149.8	99.5	(84.1-116.8)
Female	5	2.8	175.9	(56.7-410.5)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	10.9	82.9	(37.8-157.5)
Male	29	25.3	114.7	(76.8-164.8)	Female	5	7.1	70.4	(22.7-164.3)
Female	13	15.3	84.8	(45.1-145.1)	<u>Testis</u>				
<u>Larynx</u>					Male	8	6.6	120.8	(52.0-238.0)
Male	4	7.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	2.3	nc	(nc-nc)	Male	12	11.8	101.6	(52.5-177.6)
<u>Leukemia</u>					Female	35	36.9	94.7	(66.0-131.7)
Male	16	18.6	85.9	(49.1-139.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	14.5	75.6	(37.7-135.3)	Female	49	43.8	112.0	(82.8-148.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	15.7	108.0	(62.9-173.0)	Male	554	599.8	92.4	(84.8-100.4)
Female	2	5.6	nc	(nc-nc)	Female	670	663.6	101.0	(93.5-108.9)
<u>Lung and Bronchus</u>									
Male	69	80.8	85.4	(66.4-108.1)					
Female	87	90.7	95.9	(76.8-118.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.4	110.6	(40.4-240.6)	Male	2	3.9	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	18	26.4	68.1	(40.3-107.6)	Female	3	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	4	6.4	nc	(nc-nc)	<u>Ovary</u>				
Female	5	6.1	81.6	(26.3-190.5)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	21	23.4	89.6	(55.5-137.0)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.0	nc	(nc-nc)
Male	5	2.4	209.5	(67.5-489.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.7	nc	(nc-nc)	Female	5	6.0	83.3	(26.9-194.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	69	82.7	83.5	(64.9-105.6)
Female	0	0.7	nc	(nc-nc)	Female	63	83.6	75.4	(57.9-96.4)
<u>Lung and Bronchus</u>									
Male	6	10.4	57.4	(21.0-125.0)					
Female	6	11.3	53.1	(19.4-115.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.2	nc	(nc-nc)	Male	5	2.2	229.9	(74.1-536.4)
Female	3	1.1	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	12	14.2	84.5	(43.6-147.6)	Female	0	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.7	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	3.5	nc	(nc-nc)	Female	4	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	11	11.8	93.5	(46.6-167.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.0	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	45	44.7	100.6	(73.4-134.6)
Female	2	0.4	nc	(nc-nc)	Female	45	46.1	97.6	(71.2-130.6)
<u>Lung and Bronchus</u>									
Male	2	5.8	nc	(nc-nc)					
Female	4	6.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
Female	9	9.8	91.9	(41.9-174.5)	Female	1	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.5	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	6.9	72.2	(23.3-168.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	24	23.5	101.9	(65.3-151.7)
Female	0	0.3	nc	(nc-nc)	Female	24	32.4	74.1	(47.4-110.2)
<u>Lung and Bronchus</u>									
Male	2	2.8	nc	(nc-nc)					
Female	1	4.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	15.7	95.4	(53.3-157.3)	Male	8	10.8	74.1	(31.9-146.1)
Female	2	6.5	nc	(nc-nc)	Female	4	9.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.4	nc	(nc-nc)	Male	5	3.3	149.7	(48.3-349.4)
Female	2	3.0	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.8	81.9	(35.3-161.4)
Female	67	77.6	86.4	(66.9-109.7)	Female	7	9.3	75.1	(30.1-154.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	4	8.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	4.0	124.0	(39.9-289.3)
Male	12	18.5	64.9	(33.5-113.4)	<u>Ovary</u>				
Female	22	19.9	110.6	(69.3-167.5)	Female	9	6.8	131.9	(60.2-250.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	4.4	203.7	(93.0-386.7)	Male	5	5.8	86.5	(27.9-201.8)
Female	2	1.3	nc	(nc-nc)	Female	5	6.5	76.9	(24.8-179.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	40	57.0	70.2	(50.1-95.5)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.9	154.7	(56.5-336.6)
Male	8	9.6	83.2	(35.8-163.9)	Female	4	2.5	nc	(nc-nc)
Female	2	6.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.4	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<u>Leukemia</u>					Female	21	14.3	146.7	(90.8-224.3)
Male	2	6.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.4	148.4	(63.9-292.3)	Female	17	18.1	94.0	(54.7-150.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.1	82.4	(26.5-192.2)	Male	178	220.0	80.9	(69.5-93.7)
Female	4	2.2	nc	(nc-nc)	Female	234	254.6	91.9	(80.5-104.5)
<u>Lung and Bronchus</u>									
Male	26	28.2	92.1	(60.2-135.0)					
Female	39	34.1	114.3	(81.2-156.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.1	127.3	(75.4-201.2)	Male	4	9.2	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.7	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	5	8.0	62.1	(20.0-145.0)
Female	36	47.8	75.4	(52.8-104.4)	Female	3	6.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	8	6.6	121.6	(52.4-239.7)
<u>Colon / Rectum</u>					Female	4	2.6	nc	(nc-nc)
Male	18	14.9	120.6	(71.5-190.7)	<u>Ovary</u>				
Female	15	13.2	113.3	(63.4-186.9)	Female	5	4.3	116.4	(37.5-271.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.8	131.2	(42.3-306.3)	Male	4	5.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	29	48.6	59.7	(39.9-85.7)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.3	nc	(nc-nc)
Male	8	7.7	103.7	(44.6-204.3)	Female	0	1.7	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	12	8.7	138.4	(71.4-241.7)
Male	2	5.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.5	141.7	(45.7-330.6)	Female	23	11.1	207.4	(131.4-311.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.1	nc	(nc-nc)	Male	175	186.8	93.7	(80.3-108.6)
Female	3	1.4	nc	(nc-nc)	Female	162	162.9	99.5	(84.7-116.0)
<u>Lung and Bronchus</u>									
Male	37	26.0	142.6	(100.4-196.5)					
Female	25	22.9	109.2	(70.6-161.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	41.3	111.4	(81.6-148.6)	Male	30	27.9	107.4	(72.5-153.4)
Female	17	15.3	111.0	(64.6-177.7)	Female	21	23.0	91.4	(56.6-139.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	8.8	79.3	(31.8-163.4)	Male	5	8.7	57.6	(18.6-134.4)
Female	7	7.2	97.6	(39.1-201.0)	Female	6	7.0	86.1	(31.4-187.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	16	24.9	64.1	(36.6-104.2)
Female	173	178.3	97.0	(83.1-112.6)	Female	19	21.9	86.8	(52.2-135.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.3	95.2	(34.8-207.3)	Male	21	20.7	101.6	(62.8-155.3)
<u>Colon / Rectum</u>					Female	12	9.4	128.3	(66.2-224.2)
Male	56	46.3	120.9	(91.3-157.1)	<u>Ovary</u>				
Female	45	46.9	96.0	(70.0-128.4)	Female	24	15.8	151.9	(97.3-226.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	11.3	97.0	(48.4-173.7)	Male	17	14.8	114.7	(66.8-183.7)
Female	4	3.0	nc	(nc-nc)	Female	14	15.3	91.6	(50.0-153.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	3.6	247.7	(113.0-470.3)	Male	135	146.3	92.3	(77.3-109.2)
Female	2	2.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	9.9	50.4	(16.2-117.5)
Male	16	24.4	65.5	(37.4-106.4)	Female	8	6.0	133.9	(57.7-263.9)
Female	10	14.0	71.6	(34.3-131.7)	<u>Testis</u>				
<u>Larynx</u>					Male	8	6.9	115.2	(49.6-226.9)
Male	10	6.7	149.4	(71.5-274.7)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	12	11.8	101.9	(52.6-178.0)
<u>Leukemia</u>					Female	21	34.7	60.4	(37.4-92.4)
Male	14	17.4	80.5	(43.9-135.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	12.9	46.4	(16.9-100.9)	Female	47	40.2	117.0	(86.0-155.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	15.2	92.3	(50.4-154.9)	Male	570	567.2	100.5	(92.4-109.1)
Female	10	5.0	201.2	(96.3-370.1)	Female	589	595.7	98.9	(91.0-107.2)
<u>Lung and Bronchus</u>									
Male	98	75.4	130.0	(105.6-158.5)					
Female	80	82.0	97.5	(77.3-121.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	20.5	131.9	(86.9-191.9)	Male	11	12.5	87.7	(43.7-157.0)
Female	12	7.7	155.4	(80.2-271.5)	Female	8	10.1	79.1	(34.1-155.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	6	3.4	176.9	(64.6-385.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.2	80.3	(36.6-152.4)
Female	73	79.0	92.4	(72.4-116.2)	Female	11	10.5	105.1	(52.4-188.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.5	nc	(nc-nc)	Male	10	8.6	116.7	(55.9-214.6)
<u>Colon / Rectum</u>					Female	2	4.3	nc	(nc-nc)
Male	19	21.6	87.9	(52.9-137.3)	<u>Ovary</u>				
Female	18	23.5	76.5	(45.3-120.9)	Female	11	7.1	155.5	(77.5-278.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.1	137.7	(55.2-283.7)	Male	6	7.0	85.8	(31.3-186.7)
Female	2	1.5	nc	(nc-nc)	Female	5	7.9	63.3	(20.4-147.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	52	62.1	83.8	(62.5-109.8)
Female	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.7	nc	(nc-nc)
Male	13	10.3	126.3	(67.2-216.0)	Female	2	3.1	nc	(nc-nc)
Female	5	6.3	79.3	(25.5-185.0)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.2	nc	(nc-nc)
Male	7	2.9	237.9	(95.3-490.1)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	15	13.5	110.8	(62.0-182.7)
Male	8	7.8	102.5	(44.1-202.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	6.1	99.0	(36.1-215.5)	Female	21	17.5	120.0	(74.2-183.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	6.5	138.8	(63.3-263.5)	Male	237	253.2	93.6	(82.0-106.3)
Female	0	2.4	nc	(nc-nc)	Female	269	273.8	98.3	(86.9-110.7)
<u>Lung and Bronchus</u>									
Male	29	35.7	81.3	(54.4-116.7)					
Female	42	39.0	107.6	(77.5-145.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.2	115.2	(42.1-250.8)	Male	6	3.4	177.6	(64.8-386.6)
Female	0	2.0	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.0	233.9	(93.7-482.0)
Female	25	21.9	114.3	(74.0-168.7)	Female	4	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	5	5.7	87.9	(28.3-205.2)	<u>Ovary</u>				
Female	5	5.9	85.2	(27.4-198.8)	Female	3	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	8	18.9	42.3	(18.2-83.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	5	3.0	169.5	(54.6-395.5)	Female	0	0.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.8	132.6	(42.7-309.5)
Male	4	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	2	5.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	1.9	nc	(nc-nc)	Male	78	70.3	111.0	(87.7-138.5)
Female	0	0.7	nc	(nc-nc)	Female	78	74.4	104.9	(82.9-130.9)
<u>Lung and Bronchus</u>									
Male	14	9.6	145.5	(79.5-244.1)					
Female	16	10.9	146.8	(83.8-238.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.5	93.5	(37.5-192.6)	Male	2	5.2	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	4.6	nc	(nc-nc)
Female	36	33.1	108.9	(76.2-150.7)	Female	4	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	7	8.4	82.8	(33.2-170.7)	<u>Ovary</u>				
Female	8	9.7	82.9	(35.7-163.3)	Female	3	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	2.0	293.1	(107.0-638.1)	Male	4	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	18	25.2	71.6	(42.4-113.1)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.8	nc	(nc-nc)
Male	1	4.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	3	6.3	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.5	nc	(nc-nc)	Female	11	6.9	160.3	(79.9-286.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	86	102.5	83.9	(67.1-103.6)
Female	1	0.9	nc	(nc-nc)	Female	113	113.9	99.2	(81.7-119.3)
<u>Lung and Bronchus</u>									
Male	17	13.9	122.5	(71.3-196.2)					
Female	16	16.3	98.2	(56.1-159.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	99	70.7	140.1	(113.8-170.5)	Male	54	42.6	126.7	(95.2-165.4)
Female	25	24.5	102.2	(66.2-150.9)	Female	46	30.6	150.5	(110.2-200.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	11.4	96.2	(48.0-172.2)	Male	12	13.7	87.9	(45.4-153.5)
Female	11	9.4	117.6	(58.6-210.4)	Female	17	10.9	156.5	(91.1-250.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.4	nc	(nc-nc)	Male	40	37.7	106.2	(75.9-144.7)
Female	304	247.9	122.6	(109.2-137.2)	Female	45	32.6	138.0	(100.6-184.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	7.3	123.0	(56.1-233.5)	Male	32	29.4	109.0	(74.5-153.9)
<u>Colon / Rectum</u>					Female	17	13.6	124.8	(72.7-199.9)
Male	59	71.9	82.0	(62.4-105.8)	<u>Ovary</u>				
Female	71	70.5	100.7	(78.6-127.0)	Female	24	22.2	108.1	(69.3-160.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	22	18.0	122.3	(76.6-185.1)	Male	31	24.4	127.3	(86.5-180.7)
Female	3	4.7	nc	(nc-nc)	Female	21	24.4	86.2	(53.3-131.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.9	nc	(nc-nc)	Male	267	226.6	117.8	(104.1-132.8)
Female	1	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	20	16.0	124.8	(76.2-192.8)
Male	40	35.0	114.3	(81.6-155.6)	Female	9	9.1	99.2	(45.3-188.3)
Female	17	20.3	83.6	(48.7-133.9)	<u>Testis</u>				
<u>Larynx</u>					Male	9	6.1	146.8	(67.0-278.7)
Male	8	10.4	77.2	(33.2-152.2)	<u>Thyroid</u>				
Female	2	3.1	nc	(nc-nc)	Male	14	14.2	98.4	(53.7-165.1)
<u>Leukemia</u>					Female	27	38.5	70.1	(46.2-102.0)
Male	31	26.2	118.4	(80.4-168.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	29	18.4	157.9	(105.7-226.8)	Female	54	58.5	92.3	(69.3-120.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	28	22.6	123.8	(82.2-178.9)	Male	947	877.7	107.9	(101.1-115.0)
Female	7	7.6	91.9	(36.8-189.3)	Female	935	857.1	109.1	(102.2-116.3)
<u>Lung and Bronchus</u>									
Male	88	125.3	70.2	(56.3-86.5)					
Female	124	129.9	95.4	(79.4-113.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.1	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	15	23.2	64.5	(36.1-106.4)	Female	0	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	8	5.9	136.0	(58.6-268.0)	<u>Ovary</u>				
Female	3	6.7	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	18.1	104.9	(63.1-163.8)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.1	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.7	nc	(nc-nc)	Female	6	5.1	117.3	(42.8-255.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	67	70.3	95.3	(73.9-121.0)
Female	0	0.7	nc	(nc-nc)	Female	56	79.1	70.8	(53.5-92.0)
<u>Lung and Bronchus</u>									
Male	11	9.0	122.8	(61.2-219.8)					
Female	5	10.9	46.0	(14.8-107.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.2	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	8	10.8	73.9	(31.8-145.6)	Female	2	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	9.1	66.1	(24.1-143.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	6	2.5	236.7	(86.4-515.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.0	nc	(nc-nc)	Male	30	37.4	80.3	(54.1-114.6)
Female	0	0.3	nc	(nc-nc)	Female	28	35.4	79.2	(52.6-114.5)
<u>Lung and Bronchus</u>									
Male	4	5.6	nc	(nc-nc)					
Female	4	5.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	19.6	117.3	(74.3-176.0)	Male	17	11.5	148.1	(86.2-237.1)
Female	5	6.1	82.1	(26.5-191.6)	Female	2	8.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	13	10.3	125.9	(67.0-215.3)
Female	61	63.3	96.3	(73.7-123.7)	Female	6	8.2	72.9	(26.6-158.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.0	nc	(nc-nc)	Male	5	7.5	66.8	(21.5-155.9)
<u>Colon / Rectum</u>					Female	5	3.4	146.8	(47.3-342.5)
Male	20	20.3	98.4	(60.1-151.9)	<u>Ovary</u>				
Female	15	18.6	80.8	(45.2-133.2)	Female	0	5.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.6	nc	(nc-nc)	Male	7	6.5	107.1	(42.9-220.6)
Female	3	1.2	nc	(nc-nc)	Female	8	6.1	130.5	(56.2-257.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	53	51.5	102.9	(77.1-134.6)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.4	nc	(nc-nc)
Male	7	8.9	78.7	(31.5-162.2)	Female	3	2.4	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	10	10.9	91.7	(43.9-168.6)
Male	10	7.4	134.8	(64.5-247.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.8	146.0	(58.5-300.8)	Female	10	13.8	72.4	(34.7-133.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.7	nc	(nc-nc)	Male	217	227.3	95.4	(83.2-109.0)
Female	1	1.9	nc	(nc-nc)	Female	182	217.9	83.5	(71.8-96.6)
<u>Lung and Bronchus</u>									
Male	25	32.5	77.0	(49.8-113.7)					
Female	27	31.5	85.8	(56.5-124.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	15.4	65.1	(31.2-119.7)	Male	9	10.3	87.1	(39.8-165.4)
Female	4	4.3	nc	(nc-nc)	Female	6	7.5	80.5	(29.4-175.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.2	188.8	(68.9-410.9)	Male	3	3.3	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	9.2	119.7	(59.7-214.2)
Female	63	59.9	105.1	(80.8-134.5)	Female	14	6.7	208.6	(113.9-349.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	6	7.9	76.1	(27.8-165.6)
<u>Colon / Rectum</u>					Female	6	3.0	201.7	(73.7-439.1)
Male	18	17.1	105.5	(62.5-166.7)	<u>Ovary</u>				
Female	18	13.7	131.6	(77.9-208.0)	Female	5	5.2	96.9	(31.2-226.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	4.3	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	6	4.3	139.1	(50.8-302.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	48	58.0	82.7	(61.0-109.7)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	3.7	188.4	(75.5-388.1)
Male	7	9.2	76.4	(30.6-157.5)	Female	4	1.7	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	9	12.2	73.9	(33.7-140.4)
Male	5	6.3	79.4	(25.6-185.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.8	nc	(nc-nc)	Female	20	14.0	143.1	(87.4-221.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.9	nc	(nc-nc)	Male	169	214.5	78.8	(67.4-91.6)
Female	2	1.5	nc	(nc-nc)	Female	202	189.0	106.9	(92.7-122.7)
<u>Lung and Bronchus</u>									
Male	15	28.7	52.3	(29.3-86.3)					
Female	20	24.1	83.0	(50.7-128.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	15.2	78.9	(40.7-137.9)	Male	9	10.4	86.9	(39.6-165.0)
Female	3	5.6	nc	(nc-nc)	Female	10	8.8	113.7	(54.4-209.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.2	185.1	(67.6-402.9)	Male	2	3.2	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	17	9.3	183.0	(106.5-293.0)
Female	72	69.7	103.3	(80.8-130.0)	Female	11	8.2	134.8	(67.2-241.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	6	7.9	76.0	(27.8-165.5)
<u>Colon / Rectum</u>					Female	3	3.5	nc	(nc-nc)
Male	16	17.2	92.9	(53.1-150.9)	<u>Ovary</u>				
Female	17	16.7	102.0	(59.4-163.3)	Female	2	6.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.3	187.4	(80.7-369.3)	Male	6	5.5	108.7	(39.7-236.5)
Female	2	1.1	nc	(nc-nc)	Female	7	5.6	125.9	(50.5-259.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	72	55.6	129.4	(101.3-163.0)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.7	135.5	(43.7-316.1)
Male	8	9.1	87.5	(37.7-172.5)	Female	2	2.1	nc	(nc-nc)
Female	5	5.4	92.9	(29.9-216.8)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.5	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	14	13.7	101.9	(55.7-170.9)
Male	6	6.4	94.0	(34.3-204.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.8	104.0	(33.5-242.8)	Female	17	16.1	105.7	(61.6-169.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.8	86.8	(28.0-202.6)	Male	233	211.9	110.0	(96.3-125.0)
Female	0	1.9	nc	(nc-nc)	Female	212	227.0	93.4	(81.2-106.8)
<u>Lung and Bronchus</u>									
Male	30	27.8	108.1	(72.9-154.3)					
Female	21	31.1	67.5	(41.8-103.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	26.9	96.6	(63.1-141.6)	Male	16	16.9	94.6	(54.1-153.7)
Female	5	9.9	50.4	(16.3-117.7)	Female	8	14.1	56.7	(24.4-111.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.1	137.8	(55.2-284.0)	Male	6	5.3	113.7	(41.5-247.6)
Female	4	4.4	nc	(nc-nc)	Female	5	4.4	112.6	(36.3-262.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	16	15.2	105.3	(60.1-171.0)
Female	130	109.9	118.3	(98.8-140.5)	Female	10	13.9	72.2	(34.5-132.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.9	nc	(nc-nc)	Male	5	11.8	42.5	(13.7-99.1)
<u>Colon / Rectum</u>					Female	6	5.8	103.5	(37.8-225.3)
Male	21	28.8	73.0	(45.2-111.6)	<u>Ovary</u>				
Female	25	30.3	82.5	(53.4-121.8)	Female	10	9.6	103.7	(49.7-190.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.8	73.1	(23.6-170.6)	Male	10	9.3	107.3	(51.3-197.3)
Female	4	1.9	nc	(nc-nc)	Female	8	10.0	80.1	(34.5-157.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	84	85.2	98.6	(78.6-122.0)
Female	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.2	nc	(nc-nc)
Male	13	14.2	91.5	(48.7-156.5)	Female	5	3.9	128.2	(41.3-299.1)
Female	5	8.7	57.5	(18.5-134.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.4	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	7	6.3	110.4	(44.2-227.4)
<u>Leukemia</u>					Female	26	20.7	125.5	(81.9-183.8)
Male	4	10.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.2	61.1	(19.7-142.6)	Female	28	24.3	115.1	(76.5-166.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	8.6	nc	(nc-nc)	Male	293	342.3	85.6	(76.1-96.0)
Female	2	3.1	nc	(nc-nc)	Female	354	371.7	95.2	(85.6-105.7)
<u>Lung and Bronchus</u>									
Male	32	47.1	68.0	(46.5-95.9)					
Female	41	51.6	79.5	(57.0-107.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.3	nc	(nc-nc)	Male	5	4.3	117.5	(37.9-274.2)
Female	1	1.5	nc	(nc-nc)	Female	5	2.9	172.0	(55.4-401.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	30	23.7	126.5	(85.4-180.7)	Female	6	2.5	242.1	(88.4-526.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.1	nc	(nc-nc)
Male	9	7.0	128.2	(58.5-243.4)	<u>Ovary</u>				
Female	6	5.0	120.2	(43.9-261.6)	Female	0	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	22.5	84.3	(50.7-131.6)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.5	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	5	1.8	284.0	(91.5-662.8)
<u>Leukemia</u>					Female	4	5.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.5	nc	(nc-nc)	Female	7	5.3	133.1	(53.3-274.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.4	nc	(nc-nc)	Male	80	86.8	92.2	(73.1-114.7)
Female	0	0.6	nc	(nc-nc)	Female	90	72.6	124.1	(99.7-152.5)
<u>Lung and Bronchus</u>									
Male	11	11.7	94.1	(46.9-168.4)					
Female	10	9.1	110.0	(52.6-202.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.1	122.0	(39.3-284.7)	Male	7	2.6	271.8	(108.9-560.0)
Female	1	1.2	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	14	13.7	101.8	(55.6-170.9)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Ovary</u>				
Female	4	3.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	12	13.5	88.6	(45.7-154.8)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.0	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.3	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	58	52.6	110.2	(83.7-142.5)
Female	0	0.4	nc	(nc-nc)	Female	40	44.9	89.0	(63.6-121.2)
<u>Lung and Bronchus</u>									
Male	10	7.3	136.4	(65.3-250.8)					
Female	4	6.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	5	1.4	346.9	(111.8-809.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.0	256.0	(82.5-597.5)
Female	12	12.0	100.3	(51.7-175.1)	Female	3	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.3	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	16	11.6	137.8	(78.7-223.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	42	45.1	93.2	(67.1-125.9)
Female	1	0.4	nc	(nc-nc)	Female	39	40.3	96.7	(68.8-132.2)
<u>Lung and Bronchus</u>									
Male	4	6.3	nc	(nc-nc)					
Female	4	5.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	42.7	119.6	(89.0-157.2)	Male	37	27.2	136.2	(95.9-187.7)
Female	21	15.9	132.1	(81.8-202.0)	Female	33	22.6	146.0	(100.5-205.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	8.1	147.5	(76.1-257.7)	Male	12	8.5	141.0	(72.8-246.4)
Female	6	7.0	85.7	(31.3-186.5)	Female	5	7.1	70.2	(22.6-163.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.4	nc	(nc-nc)	Male	25	24.3	102.9	(66.5-151.8)
Female	176	172.3	102.2	(87.6-118.4)	Female	20	22.2	90.1	(55.0-139.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.9	nc	(nc-nc)	Male	25	19.4	128.9	(83.4-190.2)
<u>Colon / Rectum</u>					Female	14	9.3	149.7	(81.8-251.3)
Male	32	45.7	69.9	(47.8-98.8)	<u>Ovary</u>				
Female	48	48.3	99.4	(73.3-131.8)	Female	16	15.6	102.8	(58.7-167.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	11.2	116.5	(62.0-199.2)	Male	15	15.0	100.2	(56.0-165.3)
Female	5	3.1	161.5	(52.0-376.9)	Female	17	16.2	104.8	(61.0-167.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.2	nc	(nc-nc)	Male	161	139.9	115.1	(98.0-134.3)
Female	0	3.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	9.9	nc	(nc-nc)
Male	22	22.8	96.5	(60.5-146.2)	Female	4	6.3	nc	(nc-nc)
Female	18	13.6	132.3	(78.4-209.2)	<u>Testis</u>				
<u>Larynx</u>					Male	10	5.8	171.7	(82.2-315.8)
Male	6	6.4	93.7	(34.2-203.9)	<u>Thyroid</u>				
Female	3	2.1	nc	(nc-nc)	Male	13	10.4	125.3	(66.6-214.2)
<u>Leukemia</u>					Female	35	32.6	107.2	(74.7-149.1)
Male	23	17.1	134.4	(85.2-201.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	13.0	107.5	(58.7-180.3)	Female	34	39.2	86.7	(60.1-121.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	14.5	103.2	(57.7-170.2)	Male	615	553.0	111.2	(102.6-120.4)
Female	12	5.0	239.6	(123.7-418.6)	Female	648	590.2	109.8	(101.5-118.6)
<u>Lung and Bronchus</u>									
Male	84	75.5	111.3	(88.8-137.8)					
Female	95	81.5	116.6	(94.3-142.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	38.5	135.1	(100.9-177.1)	Male	30	26.2	114.4	(77.2-163.3)
Female	17	13.5	125.7	(73.2-201.3)	Female	22	21.0	104.9	(65.7-158.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	8.3	108.1	(49.3-205.2)	Male	11	8.2	134.2	(66.9-240.1)
Female	4	6.6	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	23	23.6	97.5	(61.8-146.3)
Female	158	164.9	95.8	(81.4-112.0)	Female	19	19.7	96.5	(58.1-150.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.9	nc	(nc-nc)	Male	13	20.0	64.9	(34.5-111.1)
<u>Colon / Rectum</u>					Female	9	8.4	107.1	(48.9-203.3)
Male	33	43.9	75.2	(51.7-105.6)	<u>Ovary</u>				
Female	54	41.5	130.2	(97.8-169.9)	Female	15	14.4	104.2	(58.3-171.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	10.9	82.6	(37.7-156.7)	Male	14	14.0	100.0	(54.6-167.7)
Female	2	2.7	nc	(nc-nc)	Female	10	13.5	74.0	(35.4-136.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.4	nc	(nc-nc)	Male	140	143.4	97.7	(82.2-115.2)
Female	1	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	9.3	107.5	(51.4-197.6)
Male	32	23.4	136.8	(93.6-193.2)	Female	8	5.3	151.6	(65.3-298.6)
Female	9	12.7	70.6	(32.2-134.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	6.5	nc	(nc-nc)
Male	3	6.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.9	nc	(nc-nc)	Male	14	11.3	123.6	(67.5-207.3)
<u>Leukemia</u>					Female	29	32.5	89.3	(59.8-128.2)
Male	27	16.2	166.2	(109.5-241.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	11.5	165.0	(99.3-257.6)	Female	29	37.2	78.0	(52.2-112.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	14.5	69.0	(33.0-126.9)	Male	562	539.6	104.1	(95.7-113.1)
Female	3	4.4	nc	(nc-nc)	Female	559	541.3	103.3	(94.9-112.2)
<u>Lung and Bronchus</u>									
Male	74	69.9	105.8	(83.1-132.9)					
Female	104	73.5	141.5	(115.6-171.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	7.0	171.3	(88.4-299.2)	Male	6	5.0	119.6	(43.7-260.3)
Female	5	3.1	160.6	(51.7-374.7)	Female	5	4.9	102.0	(32.9-238.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	5	4.5	111.1	(35.8-259.2)
Female	31	39.0	79.5	(54.0-112.8)	Female	4	4.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.0	nc	(nc-nc)
Male	7	8.3	84.7	(33.9-174.6)	<u>Ovary</u>				
Female	5	9.7	51.5	(16.6-120.1)	Female	4	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	2.0	391.1	(168.4-770.6)	Male	0	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	27	26.6	101.6	(66.9-147.8)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.7	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.7	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.6	nc	(nc-nc)	Female	10	8.7	114.5	(54.8-210.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	125	101.9	122.6	(102.1-146.1)
Female	0	1.0	nc	(nc-nc)	Female	117	125.8	93.0	(76.9-111.4)
<u>Lung and Bronchus</u>									
Male	20	13.2	152.0	(92.8-234.7)					
Female	13	16.2	80.1	(42.6-136.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	4.9	143.9	(57.7-296.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.0	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	17.1	111.3	(67.0-173.8)
Female	0	0.1	nc	(nc-nc)	Female	17	15.8	107.8	(62.8-172.7)
<u>Lung and Bronchus</u>									
Male	4	2.1	nc	(nc-nc)					
Female	2	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.5	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	22	19.5	113.0	(70.8-171.2)	Female	1	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	7	5.4	129.7	(52.0-267.3)	<u>Ovary</u>				
Female	2	3.9	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	24	17.8	134.9	(86.4-200.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.1	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	10	4.4	225.3	(107.9-414.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	63	65.9	95.6	(73.5-122.3)
Female	0	0.5	nc	(nc-nc)	Female	48	58.2	82.5	(60.9-109.4)
<u>Lung and Bronchus</u>									
Male	4	8.5	nc	(nc-nc)					
Female	5	7.0	71.2	(22.9-166.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	344	466.1	73.8	(66.2-82.0)	Male	253	319.6	79.2	(69.7-89.6)
Female	140	179.4	78.1	(65.7-92.1)	Female	203	294.0	69.1	(59.9-79.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	72	107.4	67.0	(52.4-84.4)	Male	114	95.7	119.2	(98.3-143.2)
Female	71	91.8	77.3	(60.4-97.5)	Female	127	81.4	156.1	(130.1-185.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	15	16.0	93.7	(52.4-154.5)	Male	284	287.5	98.8	(87.6-111.0)
Female	1903	2058.3	92.5	(88.3-96.7)	Female	256	262.0	97.7	(86.1-110.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	96	81.4	117.9	(95.5-144.0)	Male	262	225.7	116.1	(102.4-131.0)
<u>Colon / Rectum</u>					Female	114	109.2	104.4	(86.1-125.4)
Male	561	515.8	108.8	(100.0-118.2)	<u>Ovary</u>				
Female	577	549.2	105.1	(96.7-114.0)	Female	188	187.1	100.5	(86.6-115.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	118	124.3	95.0	(78.6-113.7)	Male	157	164.7	95.3	(81.0-111.5)
Female	36	34.9	103.2	(72.3-142.9)	Female	179	179.6	99.7	(85.6-115.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	61	56.6	107.7	(82.4-138.4)	Male	1865	1570.7	118.7	(113.4-124.2)
Female	48	51.2	93.8	(69.2-124.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	164	110.9	147.9	(126.1-172.3)
Male	229	268.2	85.4	(74.7-97.2)	Female	104	70.7	147.0	(120.1-178.2)
Female	172	163.8	105.0	(89.9-121.9)	<u>Testis</u>				
<u>Larynx</u>					Male	98	118.9	82.5	(66.9-100.5)
Male	90	72.5	124.2	(99.9-152.7)	<u>Thyroid</u>				
Female	17	23.7	71.7	(41.7-114.8)	Male	153	141.3	108.3	(91.8-126.9)
<u>Leukemia</u>					Female	473	475.3	99.5	(90.7-108.9)
Male	156	204.6	76.2	(64.7-89.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	129	160.0	80.6	(67.3-95.8)	Female	438	460.0	95.2	(86.5-104.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	273	164.1	166.4	(147.2-187.3)	Male	6682	6365.2	105.0	(102.5-107.5)
Female	91	58.0	156.8	(126.2-192.5)	Female	6758	7078.4	95.5	(93.2-97.8)
<u>Lung and Bronchus</u>									
Male	911	831.9	109.5	(102.5-116.9)					
Female	850	948.4	89.6	(83.7-95.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	28.1	117.4	(80.8-164.9)	Male	23	17.0	135.2	(85.7-202.9)
Female	10	10.2	98.2	(47.0-180.5)	Female	14	12.5	112.1	(61.2-188.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.7	128.6	(47.0-280.0)	Male	8	5.5	145.1	(62.5-285.9)
Female	3	3.9	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	11	15.1	72.7	(36.2-130.0)
Female	83	98.3	84.4	(67.2-104.6)	Female	9	13.4	67.2	(30.7-127.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	17	11.5	147.5	(85.9-236.2)
<u>Colon / Rectum</u>					Female	5	5.5	90.6	(29.2-211.5)
Male	21	28.6	73.4	(45.4-112.1)	<u>Ovary</u>				
Female	27	30.0	90.0	(59.3-130.9)	Female	12	8.9	134.7	(69.5-235.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	7.1	169.7	(87.6-296.5)	Male	9	9.5	94.4	(43.1-179.1)
Female	3	1.9	nc	(nc-nc)	Female	10	10.3	97.4	(46.6-179.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	90	86.3	104.3	(83.9-128.2)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.4	94.2	(34.4-205.0)
Male	9	13.8	65.1	(29.7-123.6)	Female	5	3.9	128.1	(41.3-299.0)
Female	7	8.2	85.9	(34.4-176.9)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.8	nc	(nc-nc)
Male	10	4.1	244.6	(117.1-449.8)	<u>Thyroid</u>				
Female	3	1.2	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
<u>Leukemia</u>					Female	19	15.7	120.8	(72.7-188.7)
Male	7	10.5	66.4	(26.6-136.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.8	64.3	(20.7-149.9)	Female	18	22.4	80.4	(47.6-127.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	9.0	77.6	(31.1-159.9)	Male	358	346.2	103.4	(93.0-114.7)
Female	1	3.1	nc	(nc-nc)	Female	324	347.7	93.2	(83.3-103.9)
<u>Lung and Bronchus</u>									
Male	55	49.5	111.2	(83.7-144.7)					
Female	62	52.1	119.1	(91.3-152.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.8	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	26	20.1	129.1	(84.3-189.1)	Female	3	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	5	5.6	88.9	(28.6-207.4)	<u>Ovary</u>				
Female	5	4.2	118.7	(38.2-276.9)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	19	20.3	93.8	(56.4-146.5)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.2	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.2	nc	(nc-nc)	Female	5	4.6	108.5	(35.0-253.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	61	71.8	85.0	(65.0-109.2)
Female	0	0.5	nc	(nc-nc)	Female	70	60.9	115.0	(89.7-145.3)
<u>Lung and Bronchus</u>									
Male	6	9.1	65.7	(24.0-143.1)					
Female	9	7.3	123.3	(56.3-234.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	10.1	59.1	(21.6-128.7)	Male	18	6.6	273.6	(162.0-432.4)
Female	1	2.9	nc	(nc-nc)	Female	9	4.4	205.2	(93.6-389.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
Female	41	36.4	112.6	(80.8-152.8)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	3	11.1	nc	(nc-nc)	<u>Ovary</u>				
Female	4	8.7	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.8	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	46	36.7	125.3	(91.7-167.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	3	5.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	11	6.6	166.4	(83.0-297.8)
Male	5	4.0	126.3	(40.7-294.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.4	208.2	(67.1-485.9)	Female	5	8.6	58.2	(18.8-135.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.7	nc	(nc-nc)	Male	116	136.7	84.9	(70.1-101.8)
Female	0	1.0	nc	(nc-nc)	Female	115	116.8	98.5	(81.3-118.2)
<u>Lung and Bronchus</u>									
Male	9	18.5	48.5	(22.1-92.1)					
Female	9	15.9	56.5	(25.8-107.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.0	99.3	(32.0-231.8)	Male	3	3.3	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	8	2.3	348.3	(150.0-686.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	27	18.7	144.5	(95.2-210.3)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	3	5.6	nc	(nc-nc)	<u>Ovary</u>				
Female	8	4.7	171.1	(73.7-337.2)	Female	4	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	11	17.2	63.8	(31.8-114.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.2	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.5	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	53	67.1	79.0	(59.1-103.3)
Female	0	0.5	nc	(nc-nc)	Female	72	60.2	119.6	(93.6-150.7)
<u>Lung and Bronchus</u>									
Male	3	9.0	nc	(nc-nc)					
Female	5	8.0	62.5	(20.2-146.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	40.0	129.8	(97.0-170.3)	Male	33	25.2	130.9	(90.1-183.9)
Female	24	16.5	145.5	(93.2-216.5)	Female	23	21.7	105.9	(67.1-158.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.4	94.0	(37.7-193.8)	Male	7	7.9	89.0	(35.6-183.3)
Female	5	6.7	75.1	(24.2-175.3)	Female	7	7.2	97.1	(38.9-200.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	25	22.5	111.0	(71.8-163.8)
Female	183	165.0	110.9	(95.4-128.2)	Female	21	22.1	95.0	(58.8-145.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	5.5	180.7	(86.5-332.3)	Male	21	17.6	119.5	(73.9-182.7)
<u>Colon / Rectum</u>					Female	10	9.1	109.7	(52.5-201.8)
Male	54	42.5	127.1	(95.5-165.8)	<u>Ovary</u>				
Female	67	50.1	133.7	(103.6-169.8)	Female	13	14.9	87.0	(46.3-148.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	10.2	146.9	(82.1-242.3)	Male	14	13.9	101.0	(55.2-169.4)
Female	3	3.1	nc	(nc-nc)	Female	18	16.7	107.8	(63.9-170.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.9	nc	(nc-nc)	Male	122	125.1	97.5	(81.0-116.4)
Female	4	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	9.3	107.8	(51.6-198.3)
Male	19	20.8	91.5	(55.1-142.9)	Female	7	6.5	107.3	(43.0-221.1)
Female	15	13.4	111.7	(62.5-184.2)	<u>Testis</u>				
<u>Larynx</u>					Male	5	5.1	98.0	(31.6-228.6)
Male	4	5.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	1.9	308.1	(112.5-670.6)	Male	8	9.3	85.9	(37.0-169.3)
<u>Leukemia</u>					Female	36	29.7	121.3	(84.9-167.9)
Male	10	15.9	62.7	(30.0-115.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	13.1	159.9	(99.0-244.5)	Female	36	36.4	98.9	(69.3-137.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	13.2	136.2	(80.7-215.3)	Male	528	507.5	104.0	(95.4-113.3)
Female	5	5.0	100.7	(32.5-235.0)	Female	648	579.4	111.8	(103.4-120.8)
<u>Lung and Bronchus</u>									
Male	61	70.0	87.1	(66.6-111.9)					
Female	88	82.5	106.7	(85.6-131.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	17.8	101.2	(59.9-159.9)	Male	15	10.3	145.1	(81.2-239.4)
Female	8	6.5	123.8	(53.3-243.9)	Female	13	7.5	173.6	(92.3-296.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	14	9.0	154.8	(84.5-259.7)
Female	84	60.7	138.4	(110.4-171.3)	Female	13	8.4	155.2	(82.5-265.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	7	6.7	105.0	(42.1-216.3)
<u>Colon / Rectum</u>					Female	3	3.5	nc	(nc-nc)
Male	12	17.4	69.0	(35.6-120.5)	<u>Ovary</u>				
Female	16	18.6	86.0	(49.1-139.7)	Female	4	5.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.4	nc	(nc-nc)	Male	6	5.9	101.5	(37.1-221.0)
Female	3	1.2	nc	(nc-nc)	Female	3	6.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	70	53.2	131.7	(102.7-166.4)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.9	nc	(nc-nc)
Male	6	8.2	73.1	(26.7-159.1)	Female	1	2.4	nc	(nc-nc)
Female	5	5.1	98.3	(31.7-229.3)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	7	8.7	80.8	(32.4-166.5)
Male	7	6.2	112.2	(45.0-231.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.7	126.8	(46.3-276.1)	Female	11	14.2	77.3	(38.6-138.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.4	nc	(nc-nc)	Male	213	211.4	100.7	(87.7-115.2)
Female	0	2.0	nc	(nc-nc)	Female	215	215.8	99.6	(86.8-113.9)
<u>Lung and Bronchus</u>									
Male	28	31.8	87.9	(58.4-127.1)					
Female	18	33.7	53.4	(31.7-84.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	23.7	80.1	(48.2-125.2)	Male	15	16.3	91.9	(51.4-151.6)
Female	13	7.3	177.4	(94.4-303.4)	Female	17	11.7	145.5	(84.7-233.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.3	112.7	(41.2-245.4)	Male	2	5.0	nc	(nc-nc)
Female	6	3.7	161.3	(58.9-351.0)	Female	3	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	10	14.8	67.5	(32.3-124.1)
Female	92	88.5	104.0	(83.8-127.5)	Female	12	10.8	111.5	(57.5-194.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.2	nc	(nc-nc)	Male	14	12.4	113.0	(61.7-189.6)
<u>Colon / Rectum</u>					Female	5	4.6	108.7	(35.0-253.6)
Male	23	27.1	84.8	(53.8-127.3)	<u>Ovary</u>				
Female	25	22.4	111.4	(72.1-164.4)	Female	11	7.9	139.3	(69.4-249.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.6	91.2	(33.3-198.6)	Male	13	8.6	151.0	(80.3-258.3)
Female	1	1.4	nc	(nc-nc)	Female	10	7.3	137.2	(65.7-252.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.4	nc	(nc-nc)	Male	81	84.4	96.0	(76.3-119.3)
Female	0	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.8	86.4	(27.8-201.6)
Male	8	14.4	55.6	(24.0-109.6)	Female	4	2.9	nc	(nc-nc)
Female	7	6.8	102.5	(41.1-211.3)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.5	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	11	7.2	152.4	(76.0-272.7)
<u>Leukemia</u>					Female	26	18.4	141.4	(92.3-207.2)
Male	5	10.3	48.3	(15.6-112.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.4	nc	(nc-nc)	Female	15	20.1	74.5	(41.7-122.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	8.8	158.6	(86.6-266.1)	Male	314	330.5	95.0	(84.8-106.1)
Female	3	2.4	nc	(nc-nc)	Female	304	293.9	103.4	(92.1-115.7)
<u>Lung and Bronchus</u>									
Male	51	42.4	120.2	(89.5-158.1)					
Female	29	39.1	74.1	(49.6-106.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.3	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	16	18.5	86.6	(49.5-140.7)	Female	4	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	4.5	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	10	14.1	70.7	(33.9-130.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	5	2.2	225.8	(72.8-526.9)	Female	2	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.2	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	50	50.0	100.1	(74.3-132.0)
Female	0	0.5	nc	(nc-nc)	Female	45	60.0	75.0	(54.7-100.4)
<u>Lung and Bronchus</u>									
Male	8	6.3	126.5	(54.5-249.3)					
Female	9	8.7	103.5	(47.2-196.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	81	82.4	98.3	(78.1-122.2)	Male	27	54.4	49.7	(32.7-72.2)
Female	34	31.4	108.3	(75.0-151.3)	Female	25	47.0	53.2	(34.4-78.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	17.6	96.4	(56.1-154.4)	Male	10	16.9	59.3	(28.4-109.0)
Female	18	15.0	119.8	(71.0-189.3)	Female	13	14.2	91.6	(48.7-156.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.9	nc	(nc-nc)	Male	47	49.1	95.7	(70.3-127.3)
Female	302	357.4	84.5	(75.2-94.6)	Female	37	44.8	82.6	(58.2-113.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	26	12.9	200.9	(131.2-294.4)	Male	41	39.5	103.7	(74.4-140.7)
<u>Colon / Rectum</u>					Female	20	18.9	105.9	(64.6-163.5)
Male	114	91.1	125.1	(103.2-150.3)	<u>Ovary</u>				
Female	108	96.5	111.9	(91.8-135.1)	Female	42	31.8	132.0	(95.1-178.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	20	22.0	91.0	(55.6-140.6)	Male	31	29.2	106.2	(72.2-150.8)
Female	8	6.1	131.2	(56.5-258.5)	Female	43	31.6	136.3	(98.6-183.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	7.3	68.1	(21.9-158.9)	Male	286	278.3	102.8	(91.2-115.4)
Female	5	6.3	79.3	(25.5-184.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	25	19.6	127.7	(82.6-188.5)
Male	57	46.6	122.2	(92.6-158.4)	Female	13	12.4	105.1	(55.9-179.7)
Female	27	28.3	95.4	(62.9-138.8)	<u>Testis</u>				
<u>Larynx</u>					Male	13	13.7	94.9	(50.5-162.2)
Male	19	12.8	148.0	(89.1-231.1)	<u>Thyroid</u>				
Female	4	4.2	nc	(nc-nc)	Male	32	22.2	144.1	(98.5-203.4)
<u>Leukemia</u>					Female	90	71.4	126.0	(101.3-154.8)
Male	27	35.0	77.0	(50.8-112.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	27.1	77.5	(47.9-118.4)	Female	79	79.7	99.2	(78.5-123.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	40	29.2	136.9	(97.8-186.4)	Male	1171	1104.2	106.0	(100.1-112.3)
Female	16	10.1	159.2	(90.9-258.5)	Female	1254	1209.5	103.7	(98.0-109.6)
<u>Lung and Bronchus</u>									
Male	186	146.9	126.6	(109.1-146.2)					
Female	206	165.7	124.3	(107.9-142.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.1	121.5	(39.2-283.6)	Male	4	2.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	13	15.5	83.9	(44.6-143.5)	Female	3	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	0.8	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	<u>Ovary</u>				
Female	6	4.3	140.2	(51.2-305.1)	Female	1	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	13	16.1	80.9	(43.0-138.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.8	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	41	57.2	71.7	(51.5-97.3)
Female	3	0.5	nc	(nc-nc)	Female	61	52.9	115.2	(88.1-148.0)
<u>Lung and Bronchus</u>									
Male	7	7.6	91.5	(36.7-188.6)					
Female	13	7.6	170.1	(90.5-290.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	53.0	96.3	(71.7-126.6)	Male	46	34.4	133.8	(98.0-178.5)
Female	14	22.7	61.6	(33.6-103.3)	Female	34	33.4	101.7	(70.4-142.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	10.5	114.2	(58.9-199.5)	Male	13	10.7	121.7	(64.7-208.0)
Female	12	10.4	115.5	(59.6-201.8)	Female	8	10.2	78.5	(33.8-154.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.8	nc	(nc-nc)	Male	39	30.5	127.8	(90.9-174.7)
Female	238	242.5	98.2	(86.1-111.5)	Female	38	31.9	119.2	(84.4-163.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	8.8	nc	(nc-nc)	Male	21	24.0	87.5	(54.2-133.8)
<u>Colon / Rectum</u>					Female	7	13.2	53.0	(21.2-109.1)
Male	38	55.9	68.0	(48.1-93.3)	<u>Ovary</u>				
Female	41	67.8	60.5	(43.4-82.0)	Female	33	22.1	149.0	(102.6-209.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	14.0	35.6	(11.5-83.2)	Male	17	18.5	91.9	(53.5-147.1)
Female	3	4.4	nc	(nc-nc)	Female	25	23.0	108.7	(70.4-160.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.5	nc	(nc-nc)	Male	175	180.8	96.8	(83.0-112.3)
Female	7	5.0	140.1	(56.1-288.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	12.3	64.8	(27.9-127.8)
Male	31	29.0	106.8	(72.6-151.7)	Female	9	8.8	102.4	(46.7-194.5)
Female	17	19.7	86.4	(50.3-138.4)	<u>Testis</u>				
<u>Larynx</u>					Male	14	9.0	156.3	(85.4-262.2)
Male	2	8.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	2.9	nc	(nc-nc)	Male	16	13.6	117.5	(67.1-190.9)
<u>Leukemia</u>					Female	50	49.6	100.8	(74.8-132.8)
Male	30	21.3	140.5	(94.8-200.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	26	19.1	136.4	(89.1-199.9)	Female	42	55.7	75.4	(54.4-102.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	17.9	39.1	(15.7-80.6)	Male	640	699.4	91.5	(84.6-98.9)
Female	5	7.2	69.8	(22.5-162.9)	Female	764	845.6	90.4	(84.1-97.0)
<u>Lung and Bronchus</u>									
Male	62	95.4	65.0	(49.8-83.3)					
Female	80	118.6	67.5	(53.5-84.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	11	11.9	92.8	(46.3-166.0)	Female	0	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	4	3.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	8.7	114.6	(54.9-210.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	4	1.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	30	34.0	88.2	(59.5-125.9)
Female	0	0.4	nc	(nc-nc)	Female	36	41.0	87.8	(61.5-121.6)
<u>Lung and Bronchus</u>									
Male	1	4.6	nc	(nc-nc)					
Female	5	6.2	80.5	(25.9-187.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	30.7	87.8	(57.9-127.8)	Male	18	19.2	93.6	(55.4-147.9)
Female	5	10.8	46.3	(14.9-108.2)	Female	15	14.5	103.1	(57.7-170.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.5	162.8	(74.3-309.2)	Male	7	6.1	115.7	(46.3-238.3)
Female	4	4.5	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	21	17.0	123.7	(76.6-189.1)
Female	127	115.4	110.0	(91.7-130.9)	Female	14	14.7	95.0	(51.9-159.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	12	13.1	91.9	(47.4-160.5)
<u>Colon / Rectum</u>					Female	5	6.2	80.8	(26.0-188.5)
Male	31	32.0	96.9	(65.8-137.5)	<u>Ovary</u>				
Female	27	31.7	85.3	(56.2-124.1)	Female	7	10.2	68.4	(27.4-141.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.8	nc	(nc-nc)	Male	12	10.5	113.8	(58.7-198.8)
Female	0	2.0	nc	(nc-nc)	Female	10	10.6	94.5	(45.2-173.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	97	94.8	102.3	(83.0-124.8)
Female	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	7.0	nc	(nc-nc)
Male	20	15.6	128.0	(78.2-197.7)	Female	4	4.1	nc	(nc-nc)
Female	5	9.3	53.5	(17.2-124.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.9	nc	(nc-nc)
Male	3	4.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	12	6.9	172.9	(89.2-302.0)
<u>Leukemia</u>					Female	28	20.7	135.5	(90.0-195.8)
Male	17	11.9	142.6	(83.0-228.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	8.5	82.7	(33.1-170.4)	Female	31	25.9	119.6	(81.3-169.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	10.0	100.1	(47.9-184.1)	Male	394	385.3	102.2	(92.4-112.9)
Female	3	3.4	nc	(nc-nc)	Female	392	394.2	99.5	(89.8-109.8)
<u>Lung and Bronchus</u>									
Male	40	54.5	73.4	(52.5-100.0)					
Female	63	58.3	108.1	(83.1-138.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	74.4	61.8	(45.3-82.5)	Male	56	51.6	108.5	(81.9-140.8)
Female	17	30.0	56.7	(33.0-90.9)	Female	44	49.7	88.5	(64.3-118.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	17.6	113.8	(69.5-175.7)	Male	18	15.0	119.7	(70.9-189.2)
Female	12	15.2	78.9	(40.7-137.8)	Female	7	13.6	51.5	(20.6-106.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.5	nc	(nc-nc)	Male	42	46.1	91.2	(65.7-123.2)
Female	299	338.6	88.3	(78.6-98.9)	Female	34	43.8	77.6	(53.7-108.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	13.7	65.5	(29.9-124.4)	Male	37	35.3	104.7	(73.7-144.4)
<u>Colon / Rectum</u>					Female	16	18.2	88.0	(50.3-142.9)
Male	71	80.9	87.7	(68.5-110.7)	<u>Ovary</u>				
Female	69	90.6	76.1	(59.2-96.3)	Female	21	31.2	67.3	(41.7-102.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	19.7	71.1	(38.9-119.4)	Male	32	26.1	122.5	(83.8-172.9)
Female	5	5.9	85.4	(27.5-199.3)	Female	26	30.1	86.5	(56.5-126.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	10.2	68.5	(27.4-141.1)	Male	247	250.3	98.7	(86.7-111.8)
Female	3	8.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	17.6	62.5	(31.2-111.9)
Male	33	42.4	77.8	(53.6-109.3)	Female	8	11.7	68.2	(29.4-134.4)
Female	14	27.1	51.6	(28.2-86.6)	<u>Testis</u>				
<u>Larynx</u>					Male	26	22.7	114.7	(74.9-168.1)
Male	4	11.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	4.0	nc	(nc-nc)	Male	27	23.3	115.7	(76.2-168.4)
<u>Leukemia</u>					Female	78	80.6	96.8	(76.5-120.8)
Male	26	32.8	79.2	(51.7-116.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	18	26.6	67.8	(40.1-107.1)	Female	67	76.7	87.3	(67.7-110.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	25.5	70.5	(41.7-111.4)	Male	901	1018.5	88.5	(82.8-94.4)
Female	13	9.7	133.8	(71.2-228.9)	Female	940	1176.9	79.9	(74.8-85.1)
<u>Lung and Bronchus</u>									
Male	106	132.7	79.9	(65.4-96.6)					
Female	103	158.1	65.1	(53.2-79.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	26.0	80.6	(49.9-123.2)	Male	18	16.2	111.2	(65.9-175.8)
Female	7	9.6	72.8	(29.2-150.1)	Female	16	13.0	123.0	(70.3-199.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.7	nc	(nc-nc)	Male	9	5.2	174.5	(79.6-331.2)
Female	6	4.0	148.3	(54.1-322.8)	Female	6	4.3	139.8	(51.0-304.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	10	14.5	69.0	(33.0-127.0)
Female	100	103.0	97.1	(79.0-118.1)	Female	16	13.2	121.6	(69.5-197.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.4	nc	(nc-nc)	Male	11	11.3	97.5	(48.6-174.4)
<u>Colon / Rectum</u>					Female	9	5.5	163.1	(74.4-309.7)
Male	28	27.4	102.1	(67.9-147.6)	<u>Ovary</u>				
Female	30	28.8	104.2	(70.3-148.8)	Female	6	9.1	65.6	(24.0-142.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.7	120.2	(51.8-236.9)	Male	9	9.0	100.3	(45.8-190.4)
Female	1	1.9	nc	(nc-nc)	Female	8	9.7	82.7	(35.6-163.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	83	81.9	101.4	(80.7-125.7)
Female	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	6.0	nc	(nc-nc)
Male	9	13.5	66.8	(30.5-126.7)	Female	2	3.7	nc	(nc-nc)
Female	4	8.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.9	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	10	5.9	169.5	(81.2-311.8)
<u>Leukemia</u>					Female	29	18.0	160.8	(107.7-230.9)
Male	17	10.1	167.6	(97.6-268.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	7.7	91.3	(36.6-188.1)	Female	30	23.3	128.8	(86.9-183.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	8.5	nc	(nc-nc)	Male	327	328.5	99.5	(89.0-110.9)
Female	0	3.0	nc	(nc-nc)	Female	371	351.1	105.7	(95.2-117.0)
<u>Lung and Bronchus</u>									
Male	46	45.7	100.6	(73.6-134.1)					
Female	54	50.5	106.9	(80.3-139.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;